

Publikationslista:

*** ingår i avhandlingen**

Almroth G, Lönn J, Uhlin F, Brudin L, Andersson B, Hahn-Zoric M. (2016). Sclerostin, TNF-alpha and Interleukin-18 Correlate and are Together with Klotho Related to Other Growth Factors and Cytokines in Haemodialysis Patients. *Scandinavian Journal of Immunology*. 83(1):58-63.

Nakka SS, Lönn J, Starkhammar Johansson C, Bengtsson T, Nayeri F. (2015). Antibodies produced in vitro in the detection of periodontal bacteria by using surface plasmon resonance analysis. *Clinical and Experimental Dental Research*. 1(1):32-44.

Ramezani A, Nägga K, Hansson O, Lönn J, Sjöwall J, Katoozian F, Mansouri S, Nayeri F. (2015). Hepatocyte growth factor in cerebrospinal fluid differentiates community-acquired or nosocomial septic meningitis from other causes of pleocytosis. *Fluids Barriers CNS*. 12:22.

Evers E, Lönn J, Wu C, Nayeri F. (2015). Periodontitis, an often-overlooked reservoir for bacteria, in a patient with decubital ulcer. *Cytokine*. 71(1):8-15.

Sorour AE, Lönn J, Nakka SS, Nayeri T, Nayeri F. (2015). Evaluation of hepatocyte growth factor as a local acute phase response marker in the bowel: The clinical impact of a rapid diagnostic test for immediate identification of acute bowel inflammation. *Cytokine*. 71(1):8-15.

Khalaf H, Lönn J, Bengtsson T (2014). Cytokines and chemokines are differentially expressed in periodontitis patients: possible role for TGF- β 1 as a marker for disease progression. *Cytokine*. 67(1):29-35.

Lönn J, Nakka S, Olsson H, Bengtsson T, Almer S, Nayeri F. (2013). Differences in the expression of hepatocyte growth factor in acute and chronic bowel inflammation – implications for diagnosis? *Advances in Bioscience and Biotechnology*, 4(8B):33-42

*Lönn J, Starkhammar Johansson C, Nakka S, Palm E, Bengtsson T, Nayeri F, Ravald N. (2013). High concentration, low biological activity of hepatocyte growth factor in periodontitis. *Journal of Periodontology*. 85(1):113-22.

Almroth G, Lönn J, Uhlin F, Nayeri F, Brudin L, Andersson B, Hahn-Zoric M. (2013). Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor: inflammation markers in chronic hemodialysis patients? *Scandinavian Journal of Immunology*. 78(3):285-90.

*Lönn J, Shahzad F, Uhlin F, Bengtsson T, Almroth G, Nayeri F. (2012). High concentration but low biological activity of hepatocyte growth factor in patients with chronic renal failure. *Advances in Bioscience and Biotechnology*. 3:516-23.

*Lönn J, Starkhammar Johansson C, Kälvegren H, Brudin L, Skoglund C, Garvin P, Särndahl E, Ravald N, Richter A, Bengtsson T, Nayeri F. (2012). Hepatocyte growth factor in patients with coronary artery disease and its relation to periodontal condition. *Results in Immunology*. 2:7-12.

Lönn J, Almroth G, Brudin L, Nayeri F. (2012). An Antithrombin III product containing biologically active hepatocyte growth factor may be beneficial in deep ulcer infections. *Cytokine*. 60(2):478-86.

*Börgeson E, Lönn J, Bergström I, Patcha Brodin V, Ramström S, Nayeri F, Särndahl E, Bengtsson T. (2011). Lipoxin A4 inhibits *Porphyromonas gingivalis*-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression. *Infection and Immunity*. 79(4):1489-97.

Nilsberth C, Elander L, Hamzic N, Norell M, Lönn J, Engström L, Blomqvist A. (2009). The role of interleukin-6 in lipopolysaccharide-induced fever by mechanisms independent of prostaglandin E2. *Endocrinology*. 150(4):1850-60.